Greater Asia News
Lemonex announces approval of IND application for mRNA-DegradaBALL vaccine, LEM-mR203, phase 1 clinical trial
Lemonex Inc., a biotechnology company developing innovative messenger RNA (mRNA) and siRNA therapeutics based on a novel nanoparticle drug delivery system announced on the 9th of August that an Investigational New Drug (IND) application has been approved by the Ministry of Food and Drug Safety (MFDS) for mRNA vaccine LEM-mR203 with its nano-drug delivery technology, DegradaBALL® on 21st of July.
Astellas to Open New Life Sciences Facility in DivcoWest’s Cambridge Crossing Neighborhood
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and DivcoWest, a DivCore Capital Company, announced today plans for Astellas to open a new state-of-the-art life sciences facility at 441 Morgan Avenue, in the Cambridge Crossing (CX) neighborhood in Cambridge, Mass.
Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732
Sosei Group Corporation (“the Company”; TSE: 4565), the world-leader in GPCR-focused structure-based drug design (SBDD) and development, and Cancer Research UK, the world’s largest independent funder of cancer research, today announce that the first patient has been dosed in a Phase I/IIa clinical trial evaluating Sosei Heptares’ orally available small molecule cancer immunotherapy drug HTL0039732 for advanced solid tumors.
Meiji Seika Pharma Announces Positive Results in Phase II Study of ME3183, a Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Moderate-to-Severe Plaque Psoriasis in the United States and Canada
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi) today announced that ME3183, a novel highly-potent selective phosphodiesterase-4 (PDE4) inhibitor, met the primary endpoint based on “PASI-75”, defined as the proportion of subjects achieving 75% improvement in Psoriasis Area Severity Index (PASI), in phase II clinical trial in patients with moderate-to-severe plaque psoriasis conducted in the United States and Canada.
ALR Technologies Announces Canadian Launch Plans for the GluCurve Pet CGM
ALR Technologies SG Ltd. (“ALRT” or the “Company”) (OTCQB:ALRTF), the diabetes management company, announces plans to launch the GluCurve Pet CGM (“GluCurve”) in Canada during Q3 2023 with a direct to veterinarian clinic sales model through GluCurve.ca.
Game-changing Indian MRI Scanner Launched: Targets 6 billion People without Access to Cutting-edge Imaging Technologies
India-based company Voxelgrids has launched an advanced and affordable MRI scanner with the potential to revolutionize healthcare accessibility not only in India but also worldwide.
Novo Holdings Increases Investment in Halodoc to Strengthen Indonesia’s Health System
Novo Holdings today announced that it has increased its investment in Halodoc, an Indonesia-based healthtech platform, by joining the US $135 million Series D funding round led by Astra International Tbk (Astra).
Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2023
Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2023.
Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar | Organon
Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced topline results from the interchangeability study for SB5, a biosimilar to Humira® (adalimumab). The Phase 4, randomized, double-blind, parallel-group, multiple-dose, active comparator, multicenter clinical study (NCT05510063) for SB5 was conducted across 33 sites in four countries (Bulgaria, Czechia, Lithuania, Poland) from August 2022 to May 2023 in patients with moderate to severe chronic plaque psoriasis.
MANA Develops Novel “Drycell” Microdroplets to Make Handling Single Cell Easier
Scientists at the Research Center for Materials Nanoarchitectonics (MANA) have developed micrometer-sized "liquid marbles" that can encapsulate single to several living cells, thereby aiding single-cell studies.
